Switching from branded alendronate or risedronate to generic alendronate: Effect on persistence with bisphosphonate therapy in Germany

被引：0
|
作者：
Ziller, V. [1 ]
Schuessel, K.
Czeche, S.
Franzmann, A.
Kloeckner, D.
Quinzler, R.
Schulz, M. [2 ]
Moehrke, W. [3 ]
Hadji, P. [1 ]
机构：
[1] Univ Hosp Giessen & Marburg, Dept Gynecol, Marburg, Germany
[2] DAPI Verein Deutsch Arzneiprufungsinst eV, Eschborn, Germany
[3] Procter & Gamble Pharmaceut, Schwalbach A Ts, Germany
来源：
BONE | 2009年 / 44卷 / 02期
关键词：
D O I：
10.1016/j.bone.2009.03.423
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S449 / S450
页数：2
相关论文
共 50 条
  • [41] Effect of enzyme therapy and combination therapy with alendronate on the ovariectomized rats
    Svik, K
    Rovenska, E
    Stancikova, M
    Istok, R
    Rovensky, J
    Veselkova, Z
    BONE, 2001, 28 (05) : S224 - S225
  • [42] Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate
    Kamatari, Masayuki
    Koto, Shiro
    Ozawa, Nobuhiro
    Urao, Chie
    Suzuki, Yumiko
    Akasaka, Eri
    Yanagimoto, Kae
    Sakota, Kazumi
    JOURNAL OF BONE AND MINERAL METABOLISM, 2007, 25 (05) : 302 - 309
  • [43] Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate
    Masayuki Kamatari
    Shiro Koto
    Nobuhiro Ozawa
    Chie Urao
    Yumiko Suzuki
    Eri Akasaka
    Kae Yanagimoto
    Kazumi Sakota
    Journal of Bone and Mineral Metabolism, 2007, 25 : 302 - 309
  • [44] PERSISTENCE LONG-TERM OF ALENDRONATE THERAPY ON OSTEOPOROTIC POPULATION IN TUSCANY REGION
    Marcucci, G.
    Cianferotti, L.
    Gronchi, G.
    Parri, S.
    Brandi, M. L.
    OSTEOPOROSIS INTERNATIONAL, 2015, 26 : S375 - S376
  • [45] PERSISTENCE, COMPLIANCE AND BISPHOSPHONATE SWITCHING IN PATIENTS WITH MULTIPLE MYELOMA (MM) IN GERMANY
    Intorcia, M.
    Ansorge, S.
    Giannopoulou, C.
    Hohmann, D.
    VALUE IN HEALTH, 2017, 20 (09) : A463 - A463
  • [46] Cost-effectiveness of risedronate, alendronate and raloxifene in treatment of post-menopausal women with established osteoporosis in Germany
    Brecht, JG
    Kruse, HP
    Möhrke, W
    Oestreich, A
    Huppertz, E
    OSTEOPOROSIS INTERNATIONAL, 2003, 14 : S59 - S59
  • [47] The effect of alendronate, risedronate, and raloxifene on renal functions, based on the Cockcroft and Gault method, in postmenopausal women
    Yanik, Burcu
    Bavbek, Nukhet
    Yanik, Tugra
    Inegol, Ilknur
    Kanbay, Mehmet
    Turgut, Faruk Hilmi
    Uz, Ebru
    Akcay, Ali
    RENAL FAILURE, 2007, 29 (04) : 471 - 476
  • [48] Effectiveness of Bisphosphonates on Nonvertebral and Hip Fractures in the First Year of Therapy: the Risedronate and Alendronate (REAL) Cohort Study
    Finkenstedt, Gerd
    JOURNAL FUR MINERALSTOFFWECHSEL, 2008, 15 (01): : 61 - 63
  • [49] Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: The risedronate and alendronate (REAL) cohort study
    Silverman, S. L.
    Watts, N. B.
    Delmas, P. D.
    Lange, J. L.
    Lindsay, R.
    OSTEOPOROSIS INTERNATIONAL, 2007, 18 (01) : 25 - 34
  • [50] Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: The risedronate and alendronate (REAL) cohort study
    S. L. Silverman
    N. B. Watts
    P. D. Delmas
    J. L. Lange
    R. Lindsay
    Osteoporosis International, 2007, 18 : 25 - 34
12345